Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.…
Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design
Recursion Pharmaceuticals (NASDAQ: RXRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 600 employees.
The shares were at 2.450 USD on 20 November 2026, down 47.0% over 52 weeks. Its 52-week range is 2.440 USD to 5.240 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.53B USD.
Recursion Pharmaceuticals reports return on equity of -57.0% and revenue up 258.5% year over year.
It holds more cash than debt, a net cash position of 475.15M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 6.767 USD is 176.2% above the current price. The next earnings report is expected on 24 February 2027.